Abstract 575P
Background
The data for dacomitinib, a second-generation EGFR-TKI, treating patients with advanced non-small cell lung cancer (NSCLC) and brain metastasis was lacking. This study aimed to explore the efficacy and safety of dacomitinib in treating EGFR-mutated advanced NSCLC with brain metastasis in first-line settings.
Methods
Eligible patients were treatment-naïve advanced NSCLC patients with ≥1 brain metastasis no less than 5mm treated with dacomitinib. The primary endpoint was intracranial objective response rate (iORR). Secondary endpoints included intracranial progression-free survival (iPFS), intracranial disease control rate (iDCR), sytemic ORR and DCR, PFS, overall survival (OS), and safety. Response was evaluated per modified Response Evaluation Criteria in Solid Tumors (mRECIST, version 1.1) and Response Assessment in Neuro-oncology, Leptomeningeal Metastasis (RANO-LM) criteria.
Results
Between Jul 2nd, 2019, and Sep 30th, 2022, a total of 87 treatment-naïve patients from four hospitals were included. Data cutoff date was Mar 24th, 2023. Median follow-up time was 17.5 (1.6-34.7)months. For 87 patients with evaluable brain metastasis, iORR was 89.7% and iDCR was 97.7%per mRECIST criteria. Based on RANO-LM criteria, iORR was 71.3% and iDCR was 97.7%. Median iPFS was 26.0 months, and the 1-year and 2-year iPFS rate were 68.9% and 51.5%, respectively. For 75 patients with evaluable extracranial lesions, systemic ORR was 73.8% and DCR was 96.4%. Systemic median PFS was 14.0 months and median OS was 34.0 months (Table). Overall, 86 of 87 (98.9%) patients experienced adverse events (AEs) of any grade. Most AEs were grade 1-2 and no patients died due to severe AEs. The most common (≥20%) AEs included rash (89.7%), oral ulcer (74.2%), diarrhea (67.8%), paronychia (59.8%). Table: 575P
Summary of intracranial and systemic efficacy
| Intracranial efficacy (N=87) | Systematic efficacy (N=75) | ||
| per mRECIST criteria | per RANO-BM criteria | ||
| Complete response, n (%) | 42 (48.3) | 42 (48.3) | 2 (2.7) |
| Partial response, n (%) | 36 (41.8) | 20 (23.0) | 51 (68.0) |
| Stable disease, n (%) | 7 (8.0) | 23 (26.4) | 21 (28.0) |
| Objective response rate(95%CI) | 89.7 (81.3-95.2) | 71.3 (60.6-80.5) | 73.8 (63.1-82.8) |
| Disease control rate (95%CI) | 97.7 (91.9-99.7) | 97.7 (91.9-99.7) | 96.4 (89.9-99.3) |
| Progression-free survival, median (95%CI) | 26.0 (22.5-29.5) | 14.0 (11.1-16.9) | |
| One-year progression-free survival rate | 68.9% | 53.1% | |
| Two-year progression-free survival rate | 51.5% | 24.1% |
Conclusions
Dacomitinib showed promising efficacy and manageable safety profile for advanced NSCLC with brain metastasis harboring EGFR mutation in the first-line treatment.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
484P - Treatment (tx) patterns and outcomes in resectable early-stage EGFR-mutated (EGFRm) NSCLC in South Korea: Subgroup analysis of a global real-world (rw) study
Presenter: Myung-Ju Ahn
Session: Poster Display
Resources:
Abstract
485P - LDCT lung cancer screening of never-smokers meta-analysis subgroup analysis: Adenocarcinoma is the highly predictive histology identified in never-smokers
Presenter: Sai-Hong Ou
Session: Poster Display
Resources:
Abstract
486P - Fiscal feasibility and implications of integrating lung cancer screening into Hong Kong’s healthcare system
Presenter: Herbert Ho Fung Loong
Session: Poster Display
Resources:
Abstract
487P - Evaluating the performance of the USPSTF lung cancer screening guidelines in an Asian population of lung cancer patients
Presenter: Jian Wei Tan
Session: Poster Display
Resources:
Abstract
488P - Pulmonary ground glass opacity lesions: Immune ecosystem and its clinical relevances of early-stage lung adenocarcinoma
Presenter: Shensi Shen
Session: Poster Display
Resources:
Abstract
489TiP - BGB-LC-202 (NCT05577702): Phase II Umbrella study of tislelizumab (TIS) monotherapy and TIS-based immunotherapy combinations +/- chemotherapy (CT) as neoadjuvant treatment in Chinese patients (pts) with resectable stage II to IIIA non-small cell lung cancer (NSCLC)
Presenter: Wentao Yu
Session: Poster Display
Resources:
Abstract
491P - Furmonertinib as adjuvant therapy for elderly patients in resected EGFR-mutated non-small cell lung cancer: A double-center, real-world experience
Presenter: Ziheng Wu
Session: Poster Display
Resources:
Abstract
492P - Penpulimab-based combination neoadjuvant/adjuvant therapy for patients with resectable locally advanced non-small cell lung cancer: Preliminary results from a phase II study (ALTER-L043)
Presenter: Changli Wang
Session: Poster Display
Resources:
Abstract
493P - The prognostic value of 4L lymph node dissection in left-sided operable non-small cell lung cancer: A systematic review and meta-analysis
Presenter: Lei Peng
Session: Poster Display
Resources:
Abstract
495P - Intrinsic STING of CD8+T cells regulates self-metabolic reprogramming and exerts anti-tumor effects
Presenter: Qiuli Xu
Session: Poster Display
Resources:
Abstract